Test Price
900 AED✅ Home Collection Available
Fluorescence In-Situ Hybridization (FISH) for Prenatal & Postnatal Diagnosis of Chromosomes 13 & 21 – 900 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139) for reliable detection of trisomies 13 and 21.
- Premium Logistics: Hospital extraction only – sample collection conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Telephonic post‑test guidance in result interpretation aligned with DHA and MOHAP prenatal care pathways.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
Fluorescence In-Situ Hybridization (FISH) rapidly screens for numerical abnormalities of chromosomes 13 (Patau syndrome) and 21 (Down syndrome) in both prenatal and postnatal samples. The assay uses direct fluorescent probes on interphase nuclei, providing a fast and accurate count of these chromosomes without requiring cell culture.
For prenatal diagnosis, samples are obtained via amniocentesis or chorionic villus sampling under continuous ultrasound guidance. Postnatal testing uses a simple peripheral blood draw. All invasive collection procedures are performed exclusively within accredited hospital facilities to ensure maximum safety.
| Feature | Our FISH Test (Premium) | Standard Karyotype (Alternative) |
|---|---|---|
| Target | Specific aneuploidy 13 & 21 | All chromosomes, structural anomalies |
| Methodology | Direct fluorescent probes on interphase nuclei | Cell culture, G‑banding analysis |
| Turnaround Time | 10–12 days | 14–21 days |
| Sample Types | Amniotic fluid, CVS, peripheral blood | Amniotic fluid, CVS, blood (with culture) |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics specialist, I understand the anxiety that comes with prenatal screening for chromosomal abnormalities. This FISH assay provides a rapid, highly accurate initial assessment for trisomies 13 and 21, allowing families and physicians to make informed decisions earlier. However, a positive FISH result should always be confirmed with a full karyotype and interpreted alongside detailed clinical and ultrasound findings – no single test offers a complete diagnosis.” — Lina Osama Zaki Quteineh, DHA Registration ID: 9294403
Advisory: Medication & Supplement Guidance
Do not discontinue prescribed medication without consulting your doctor. No routine medication interferes with FISH analysis, but any change in prenatal supplements or anticoagulants should be managed by your treating physician.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inability to provide informed consent (including minors without legal guardian consent); current infection at the needle‑insertion site; uncorrected coagulopathy; suspected intra‑amniotic infection.
- ER Red Flags (post‑procedure): Sudden severe abdominal pain, heavy vaginal bleeding, fever ≥38.5°C, or clear fluid leakage – seek emergency medical care immediately.
Patient FAQ & Clinical Guidance
1. What does the FISH test for chromosomes 13 and 21 diagnose?
This FISH test rapidly detects aneuploidies of chromosomes 13 and 21, aiding prenatal screening for Patau syndrome (trisomy 13) and Down syndrome (trisomy 21). The test uses fluorescent DNA probes that bind to specific regions of these chromosomes in uncultured cells, providing a fast, accurate count. Early results support clinical decisions and genetic counseling.
2. How is the sample collected for this FISH test, and is it painful?
For prenatal diagnosis, a specialist obtains amniotic fluid or chorionic villi using a thin needle under continuous ultrasound guidance – most patients describe a brief cramp or pressure. Postnatal testing uses a simple peripheral blood draw. Because invasive prenatal procedures carry inherent risks, all collections are performed strictly within an accredited hospital facility. Mobile home phlebotomy is not available for this test.
3. How accurate is FISH for trisomy 21 compared to full chromosome analysis?
FISH demonstrates over 99% sensitivity for trisomy 21, but it cannot detect structural chromosome rearrangements or mosaicism. A negative FISH result does not rule out other chromosomal abnormalities. A complete karyotype remains the gold standard and is often performed in parallel. Combining both provides the most comprehensive fetal genetic assessment.
UAE Regulatory & Data Privacy Adherence
All genetic test results are processed under the strict data protection framework mandated by Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient data is anonymized, encrypted, and never shared without explicit written consent. Clinical safety and patient consent procedures comply with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | Fluorescence In-Situ Hybridization (FISH) for Chromosomes 13 & 21 – Prenatal & Postnatal |
| Price (AED) | 900 |
| Turnaround Time | 10–12 business days |
| Sample Type / Matrix | Amniotic fluid, Chorionic villus sample, Peripheral blood |
| Methodology Used | Fluorescence In-Situ Hybridization (FISH) – direct probes on interphase nuclei |
| ICD-10-CM Code | Q90.9 (Trisomy 21, unspecified), Q91.7 (Trisomy 13, unspecified) |
| LOINC Code | 49498-0 (FISH for aneuploidy panel) |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians